Sector News

Merck offers EU concessions over $17 bln Sigma-Aldrich buy

May 28, 2015
Life sciences
(Reuters) – German drugmaker Merck has offered concessions in a bid to convince European Union antitrust regulators to clear its proposed $17 billion acquisition of U.S. peer Sigma-Aldrich Corp.
 
Earlier this month, Merck said the European Commission expressed concerns “of a limited nature” over its biggest ever takeover. It submitted concessions on May 22, according to a filing on the EU executive’s website. No details were provided.
 
The EU competition watchdog will now decide by June 15 instead of June 1 whether to approve the takeover.
 
Companies typically offer to sell overlapping assets or provide rivals access to technologies or patents to allay regulatory worries that the merged entity may have an excessive market share. (Reporting by Foo Yun Chee. Editing by Jane Merriman)

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend